In a landmark move, President Trump signs an Executive Order aimed at reducing prescription drug prices for Americans, aligning them with those in other wealthy nations. This initiative seeks to curb unfair pricing practices and ensure a fair deal for U.S. patients.
President Trump signs an executive order reviving the 'most favored nation' policy to slash drug costs by linking U.S. prices to lower prices abroad. Will this finally bring relief to American patients?
President Trump is set to sign an executive order aiming to lower drug prices in the US by aligning them with prices in wealthy nations. This 'most favored nation' model could face legal challenges.
Casey Means, a controversial figure in the health sector, faces backlash from MAGA influencers and former allies as she advocates for lifestyle changes to prevent chronic diseases. Discover the tensions surrounding her nomination and her views on vaccines.
In a pivotal court ruling, Judge Mark Pittman denied compounding pharmacies' request for an injunction against the FDA's decision on the semaglutide shortage. This ruling keeps strict timelines for exiting the market, leaving many in the industry concerned.
As President Trump prepares to unveil a major tariff plan, pharmaceutical companies are lobbying for a gradual implementation to mitigate the impact on drug prices and supply. With potential tariffs looming, how will the industry adapt?
Eli Lilly is set to unveil results from trials of orforglipron, its groundbreaking once-daily obesity pill, potentially revolutionizing weight loss treatment by offering a needle-free alternative. Analysts predict it could capture a significant share of the $150 billion GLP-1 market.
Eli Lilly to invest $27 billion in building new US manufacturing plants amid challenges from drug import duties. The move aligns with Trump's push for American manufacturing revitalization.
